Dirk Kreder was appointed president of the Polish biotechnology company Mabion. New president of Mabion Dirk Kreder has extensive experience in managing small and large pharmaceutical companies in Europe and the United States. He has contributed to the development and registration of biosimilar and generic drugs on markets in several dozen countries. He has 10…
Due to the relatively small number of drugs and the high barriers to entry, the market for biological medicines is highly concentrated compared to other pharmaceutical market sectors. In the first half of 2019, the top three manufacturers controlled about 35% of the segment in value terms, according to the PMR report “Biological and biosimilar…
PMR presents a set of infographics from the report: Biological and biosimilar medicines market in Poland 2019. Market analysis and development forecasts for 2019-2024.
According to the forecasts presented in PMR’s latest report “Biological and biosimilar medicines market in Poland 2019. Market analysis and development forecasts for 2019-2024”, sales of biological drugs (reference and biosimilar) will exceed PLN 4.8bn in 2019. Penetration of biosimilars is increasing In 2018, the development of the biological drugs market was hampered by the…
Introduction of biosimilar drugs to reimbursement in Poland takes almost the longest time in Europe. Nevertheless, obtaining reimbursement is a key factor in the development of business activities of companies, among which PMR conducted a survey specifically for the report “Biological and biosimilar medicines market in Poland in 2019. Market analysis and development forecasts for…
Zentiva, one of the leading generic manufacturers in Europe, has announced the signing of the final acquisition agreement for Alvogen’s business in Central and Eastern Europe (CEE). The transaction is expected to be closed in the first quarter of 2020. Alvogen will focus on Asia and biosimilars The Alvogen portfolio includes around 200 products. They…
Artur Chabowski resigned from the position of President of Mabion, a Polish biotechnology company. It will come into force on 30 June. Artur Chabowski: My mission fulfilled Artur Chabowski’s decision is related to the completion of one of the key steps towards the registration of the biosimilar MabionCD20 in Europe. “I feel that my mission…
A hospital should use biological drugs if the criterion for their replacement with biosimilar drugs is the price. After the last judgment of the Provincial Administrative Court, the discussion on the possibility of substitution of biological drugs has reopened. Producers, service providers and payers participate in the discussion. The Court upheld the decision of the…
On 14 November, Mabion announced that it had received a permit to build “Centrum Naukowo-Technologiczny Zaawansowanej Biotechnologii Medycznej Mabion SA” in Konstantynow Lodzki. Thanks to this, the company may begin work on the extension of the existing plant of the Scientific and Industrial Complex of Medical Biotechnology. As a result, the production and research and…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.